To evaluate the clinical efficacy of transjugular intrahepatic portosystem shunt (TTPS) and gastric coronary vein embolization (GCVE) in the treatment of patients with cirrhosis, portal hypertension and upper gastrointestinal bleeding.

From Jan 2014 to May 2017 72 patients were enrolled and divided into the TIPS group (36 cases, receiving TIPS) and TIPS + E group (36 cases, by TIPS + GCVE) .

Portal vein diameter (1.21 ± 0.08) cm vs. (1.26 ± 0.09) cm, portal pressure (23.9 ± 2.1) cmH₂O vs. (25.1 ± 2.2) cm H₂O and congestion index (0.06 ± 0.03) cm/s vs. (0.08 ±0.03) after 1 month of treatment in TIPS + E group was significantly lower than the TIPS group, and the portal vein velocity was significantly higher than that of the TIPS group (42 ±6) cm/s vs. (38 ±7) cm/s, t= 2.491, 2.367, 2.828, t= 2.343, all P < 0.05. The Child-Pugh score in the TIPS + E group was significantly lower than that in the TIPS group (7.9 ± 1.4) vs. 8.6 ± 1.6, t = 2.074, P = 0.042). There was no statisticall different difference in postoperative hepatic encephalopathy in the two groups (17% vs. 11%, χ² = 0.465, P = 0.496 ). The one-year rebleeding rates in the TIPS group and the TIPS + E group were 14% and 3%, respectively. The risk of rebleeding in the TIPS + E group was significantly lower than that in the TIPS group (HR =0.218, P =0.041) . The one-year access obstruction rates in the TIPS group and the TIPS + E group were 17% and 14%, respectively. (P =0.679) . The all-cause mortality rates of the TIPS group and the TIPS + E group were 8% and 3%, respectively, showing no statistically (P =0.299) .

TIPS + GCVE therapy in the treatment of portal hypertensive upper gastrointestinal bleeding effectively reduces the risk of rebleeding.

Hypertension, portal; Portosystemic shunt, transjugular intrahepatic; Embolization, therapeutic